Risk factors for development of vancomycin-resistant enterococcal bacteremia among VRE colonizers A retrospective case control study

被引:7
|
作者
Kaya, Abdurrahman [1 ]
Kaya, Sibel Yildiz [2 ]
Balkan, Ilker Inanc [3 ]
Bayramlar, Osman Faruk [4 ]
Mete, Bilgul [3 ]
Saltoglu, Nese [3 ]
Aygun, Gokhan [5 ]
Tabak, Omer Fehmi [3 ]
机构
[1] Istanbul Training & Res Hosp, Dept Infect Dis, Istanbul, Turkey
[2] Sungurlu State Hosp, Dept Infect Dis, Corum, Turkey
[3] Istanbul Univ, Med Sch Cerrahpasa, Dept Infect Dis, Istanbul, Turkey
[4] Istanbul Univ, Istanbul Med Fac, Publ Hlth Dept, Istanbul, Turkey
[5] Istanbul Univ, Med Sch Cerrahpasa, Dept Med Microbiolog, Istanbul, Turkey
关键词
Enterococci; Colonization; Vancomycin resistance; BLOOD-STREAM INFECTION; COLONIZATION; EPIDEMIOLOGY; SURVEILLANCE; LIVER; HEMATOLOGY; HOSPITALS; FAECIUM; IMPACT;
D O I
10.1007/s00508-020-01733-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims We aimed to determine the proportion of vancomycin-resistant enterococci (VRE) colonized patients among all inpatients who later developed VRE bacteremia during hospital stay and to identify the risk factors for VRE bacteremia at a tertiary hospital. Material and methods Patients with positive rectal screening or any clinically significant positive culture results for VRE were included in 1-year follow-up. Colonization with VRE was defined as a positive culture (rectal, stool, urinary) for VRE without infection and VRE bacteremia was defined as positive blood culture if the signs and symptoms were compatible with infection. To determine the risk factors for VRE bacteremia among VRE colonized patients, a retrospective case control study was performed. The two groups were compared in terms of variables previously defined as risk factors in the literature. Results Of 947 positive samples, 17 VRE bacteremia were included in the analysis. Cephalosporin use for more than 3 days within 3 months was a significant risk factor for bacteremia (p= 0.008). Prior use of carbapenems was found to be statistically significant for bacteremia (p= 0.007). In multivariate analyses the use of carbapenems and cephalosporins was an independent risk factor for developing bacteremia among VRE colonizers (odds ratio, OR, 6.67; 95% confidence interval, CI, 1.30-34;p= 0.022 and OR 4.32, 95% CI 1.23-15;p= 0.022,respectively). Conclusion A VRE colonization in patients receiving broad-spectrum beta-lactam antibiotics including carbapenems and cephalosporins may result in bacteremia. It is possible to keep mortality at very low levels in VRE bacteremia with effective infection control measures, rapid infectious diseases consultation and rational antimicrobial treatment based on current epidemiological data.
引用
收藏
页码:478 / 483
页数:6
相关论文
共 50 条
  • [1] Risk factors for development of vancomycin-resistant enterococcal bacteremia among VRE colonizersA retrospective case control study
    Abdurrahman Kaya
    Sibel Yıldız Kaya
    Ilker Inanç Balkan
    Osman Faruk Bayramlar
    Bilgül Mete
    Neşe Saltoglu
    Gökhan Aygün
    Ömer Fehmi Tabak
    Wiener klinische Wochenschrift, 2021, 133 : 478 - 483
  • [2] Vancomycin-resistant enterococcal (VRE) bacteremia (Bact) in a chronic hemodialysis population: Incidence and associated factors.
    Woredekal, Y
    Barth, RH
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1997, 8 : A1186 - A1186
  • [3] A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia
    Bhavnani, SM
    Drake, JA
    Forrest, A
    Deinhart, JA
    Jones, RN
    Biedenbach, DJ
    Ballow, CH
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2000, 36 (03) : 145 - 158
  • [4] Surveillance at 49 US Medical Centers for vancomycin-resistant enterococcal (VRE) bacteremia.
    Edmond, MB
    Wallace, SE
    Pfaller, MA
    Jones, RN
    Wenzel, RP
    CLINICAL INFECTIOUS DISEASES, 1996, 23 (04) : 49 - 49
  • [5] Mortality (M) of vancomycin-susceptible (VSE) versus vancomycin-resistant enterococcal (VRE) bacteremia (B).
    Nimmagadda, AP
    Goetz, MB
    CLINICAL INFECTIOUS DISEASES, 1996, 23 (04) : 48 - 48
  • [6] Daptomycin Therapy for Vancomycin-Resistant Enterococcal Bacteremia: A Retrospective Case Series of 30 Patients
    Gallagher, Jason C.
    Perez, Mirza E.
    Marino, Elizabeth A.
    LoCastro, Laura G.
    Abrardo, Lauren A.
    MacDougall, Conan
    PHARMACOTHERAPY, 2009, 29 (07): : 792 - 799
  • [7] Emergence of resistance to chloramphenicol among vancomycin-resistant enterococcal (VRE) bloodstream isolates
    Lautenbach, E
    Gould, CV
    LaRosa, LA
    Marr, AM
    Nachamkin, I
    Bilker, WB
    Fishman, NO
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2004, 23 (02) : 200 - 203
  • [8] Vancomycin-Resistant Enterococcus (VRE) Transmission and Risk Factors in Contacts of VRE Carriers
    Kaki, Reham
    Yu, Yang
    O'Neill, Cindy
    Lee, Christine
    Mertz, Dominik
    INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2014, 35 (07): : 876 - 879
  • [9] Risk factors for development of vancomycin-resistant enterococcal bloodstream infection in patients with cancer who are colonized with vancomycin-resistant enterococci
    Zaas, AK
    Song, XY
    Tucker, P
    Perl, TM
    CLINICAL INFECTIOUS DISEASES, 2002, 35 (10) : 1139 - 1146
  • [10] Nosocomial vancomycin-resistant enterococcal blood stream infection (VRE-BSI) development in oncology patients colonized with vancomycin-resistant Enterococci(VRE-C)
    Zaas, AK
    Song, XY
    Perl, TM
    Tucker, PC
    CLINICAL INFECTIOUS DISEASES, 2000, 31 (01) : 278 - 278